A Community Wellness Program for Adults Living With Long-term Physical Disability (EW-D)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03653390 |
Recruitment Status :
Active, not recruiting
First Posted : August 31, 2018
Last Update Posted : February 4, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Physical Disability | Behavioral: EnhanceWellness for Disability (EW-D) Behavioral: Wellness Education | Not Applicable |
Middle-age (45-64) is a time of health vulnerability for millions of Americans. More than 50% of individuals in the U.S. will have two or more chronic conditions by age 60, contributing to increased risk of later disability. However, for individuals with long-term physical disabilities (LTPDs) such as spinal cord injury or multiple sclerosis, these risks are magnified. This vulnerable population is especially in need of interventions to promote community participation and improve disease self-management during midlife.
Over the past 5 years, our research team has adapted an evidence-based health promotion intervention designed for older adults to serve middle-aged and older adults with LTPD. The investigators now have a trial version of this intervention (called "EnhanceWellness for Disability"; EW-D) with promising findings in pilot testing, ready for a larger community trial. Through a new partnership with 3 regional Centers for Independent Living, the investigators can now test this program for people with LTPD in 14 counties in the Northwest U.S.A.
The broad, long-term aims of this study are to test the efficacy of this program relative to two control conditions (an attention-matched health education control and treatment as usual), in 600 community dwelling adults age 45-64 years with LTPD using modern outcome scales appropriate for people with LTPD. The primary outcome is the ability to participate in valued community activities. The investigators will seek to determine whether the intervention was effective and if so, what mechanisms of change drove the effect. In addition to self-report, the investigators will also collect objective measures of community activity via global positioning system (GPS) and travel diaries, in a randomly selected subset of 300 participants. This study's specific aims are as follows:
Specific Aim 1. To determine the efficacy of eight sessions of EW-D, relative to an attention control condition or treatment as usual, in middle-aged adults with LTPD. The primary outcome will be the self-reported ability to participate in valued community activities.
Specific Aim 2. To determine if observed intervention effects are due to (1) improved disease management self-efficacy, (2) decreased interference due to pain and fatigue, or (3) improvements in psychological resilience.
Secondary Analyses. To determine if 1) intervention effects are maintained at 12 months and 2) intervention effects can be detected in objective, GPS-based measures of activity (quantified as number of trips outside the home, time outside the home, area of travel, and activity in established categories). The investigators will also examine the potential moderating effects of biological sex on treatment response.
This approach is consistent with goals described in recent National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) program announcements, including those calling for age-appropriate interventions to improve self-management of chronic conditions (PA 14-344) and those calling for prevention research for adults in midlife (PA-15-098). If hypotheses are confirmed, this work would support a program that could be used to promote health and wellness in both able-bodied older adults and middle-aged adults with LTPD, which would be novel to the field and could improve reach.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 516 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | Efficacy and Mechanism of a Community Wellness Promotion Program for Middle-aged Adults Living With Long-term Physical Disability |
Actual Study Start Date : | January 31, 2019 |
Estimated Primary Completion Date : | September 30, 2022 |
Estimated Study Completion Date : | March 31, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: EnhanceWellness for Disability (EW-D)
Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
|
Behavioral: EnhanceWellness for Disability (EW-D)
Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time. |
Active Comparator: Wellness Education
Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
|
Behavioral: Wellness Education
Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations. |
No Intervention: Control
Participant continues with their lives as they normally would.
|
- Community participation (self-report) [ Time Frame: Baseline ]Complete a standardized measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form (APSR). Higher scores indicate better ability to participate in social activities (total score range: 8-40)
- Community participation (self-report) [ Time Frame: 3 months ]Complete a standardized measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form (APSR). Higher scores indicate better ability to participate in social activities (total score range: 8-40)
- Community participation (self-report) [ Time Frame: 6 months ]Complete a standardized measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form (APSR). Higher scores indicate better ability to participate in social activities (total score range: 8-40)
- Community participation (self-report) [ Time Frame: 12 months ]Complete a standardized measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form (APSR). Higher scores indicate better ability to participate in social activities (total score range: 8-40)
- Community Participation (measured) [ Time Frame: Baseline ]Global Positioning System (GPS) measurement
- Community Participation (measured) [ Time Frame: 12 months ]Global Positioning System (GPS) measurement
- Community Participation (measured) [ Time Frame: Baseline ]Self-report travel diary
- Community Participation (measured) [ Time Frame: 12 months ]Self-report travel diary
- Disease management self-efficacy [ Time Frame: Baseline ]Complete a standardized measure: University of Washington Self-Efficacy Scale. Higher score indicates better self-efficacy (total score range: 6-30)
- Disease management self-efficacy [ Time Frame: 3 months ]Complete a standardized measure: University of Washington Self-Efficacy Scale. Higher score indicates better self-efficacy (total score range: 6-30)
- Disease management self-efficacy [ Time Frame: 6 months ]Complete a standardized measure: University of Washington Self-Efficacy Scale. Higher score indicates better self-efficacy (total score range: 6-30)
- Disease management self-efficacy [ Time Frame: 12 months ]Complete a standardized measure: University of Washington Self-Efficacy Scale. Higher score indicates better self-efficacy (total score range: 6-30)
- Pain and fatigue interference [ Time Frame: Baseline ]Complete standardized measures: Patient-Reported Outcomes Measurement Information System Pain Interference short form and Patient-Reported Outcomes Measurement Information System Fatigue short form. Higher scores indicate more pain and more fatigue (total score range: 4-20)
- Pain and fatigue interference [ Time Frame: 3 months ]Complete standardized measures: Patient-Reported Outcomes Measurement Information System Pain Interference short form and Patient-Reported Outcomes Measurement Information System Fatigue short form. Higher scores indicate more pain and more fatigue (total score range: 4-20)
- Pain and fatigue interference [ Time Frame: 6 months ]Complete standardized measures: Patient-Reported Outcomes Measurement Information System Pain Interference short form and Patient-Reported Outcomes Measurement Information System Fatigue short form. Higher scores indicate more pain and more fatigue (total score range: 4-20)
- Pain and fatigue interference [ Time Frame: 12 months ]Complete standardized measures: Patient-Reported Outcomes Measurement Information System Pain Interference short form and Patient-Reported Outcomes Measurement Information System Fatigue short form. Higher scores indicate more pain and more fatigue (total score range: 4-20)
- Resilience [ Time Frame: Baseline ]Complete a standardized measure: Connor-Davidson Resilience Scale 10-item short form. Higher score indicates more resilience (total score range: 0-40)
- Resilience [ Time Frame: 3 months ]Complete a standardized measure: Connor-Davidson Resilience Scale 10-item short form. Higher score indicates more resilience (total score range: 0-40)
- Resilience [ Time Frame: 6 months ]Complete a standardized measure: Connor-Davidson Resilience Scale 10-item short form. Higher score indicates more resilience (total score range: 0-40)
- Resilience [ Time Frame: 12 months ]Complete a standardized measure: Connor-Davidson Resilience Scale 10-item short form. Higher score indicates more resilience (total score range: 0-40)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 45 to 64 years of age at screening (turning 65 years after screening is ok);
- Able to read, speak, and understand English;
-
Has a self-reported physician's diagnosis of long-term physical disability defined as:
- a medical condition affecting the muscular or neurologic systems (eg, muscular dystrophy, multiple sclerosis, post-polio syndrome or spinal cord injury), and the condition:
- creates functional disability (impairment in at least one activity of daily living (ADL) or at least one instrumental activity of daily living (IADL), as indicated by the Expanded Functional Disability Scale)
- was present before age 40 years
- Able to participate via telephone;
- Has a goal in mind if randomized to the EW-D intervention;
- Has not participated in the original EnhanceWellness intervention group.
Exclusion Criteria:
- Under 45 years of age or 65 or older at screening;
- Unable to read, speak, or understand English;
- Does not have a neurological or muscular condition affecting physical function (e.g., persons with low back pain and shoulder pain would be excluded);
- Does not have functional disability;
- Disability onset after age 40 years;
- Significant cognitive impairment as defined by the Six-Item Screener;
-
Psychiatric condition or symptoms that would interfere with participation, specifically:
- Current, active suicidal ideation with current intent to harm oneself, or
- Current schizophrenia, psychosis, or mania
- Unable to participate via telephone;
- Does not have a goal if randomized to the EW-D intervention;
- Has participated in the original EnhanceWellness intervention group.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03653390
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 98195 |
Principal Investigator: | Ivan Molton, PhD | University of Washington |
Responsible Party: | Ivan Molton, Professor, School of Medicine: Rehabilitation Medicine:Psychology, University of Washington |
ClinicalTrials.gov Identifier: | NCT03653390 |
Other Study ID Numbers: |
STUDY00003931 R01NR016942-01 ( U.S. NIH Grant/Contract ) |
First Posted: | August 31, 2018 Key Record Dates |
Last Update Posted: | February 4, 2022 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The investigators propose to make available to interested researchers a data file (de-identified to remove any variables from which it would be possible to identify any individual participant) any data used in a published article, at the time that it is accepted for publication. That is, at the request of an outside researcher, the investigators will create and share a data file that includes all of the variables used in the published article and a list of the variables in the data file (along with their variable labels). Any investigators who request these data will receive (1) a copy of the published article (which will describe the source of the data); (2) the variable list/variable labels; and (3) a data set. |
Time Frame: | Data will become available after the main study results are published. |
Access Criteria: | Although any shared data will be stripped of identifiers prior to release, given the very specific nature of the study sample (middle-aged adults with disabilities) it is possible that those who access this data could potentially identify subjects with unusual characteristics or combinations of unusual characteristics. Therefore, the investigators will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
health promotion intervention community participation quality of life middle age |
multiple sclerosis spinal cord injury muscular dystrophy post-polio syndrome |